Correspondence |

Ustekinumab Therapy for Severe Interstitial Granulomatous Dermatitis With Arthritis

Pauline Leloup, MD; Hélène Aubert, MD; Sylvie Causse, MD; Benoît Le Goff, MD, PhD; Sébastien Barbarot, MD
JAMA Dermatol. 2013;149(5):626-627. doi:10.1001/jamadermatol.2013.256.
Text Size: A A A
Published online


Interstitial granulomatous dermatitis with arthritis (IGDA) is a rare disease that was first described by Ackerman1 in 1993. Fewer than 70 cases have been reported in the literature,2 and specific therapies are not available. We report here a case of severe recalcitrant IGDA that was successfully treated with ustekinumab.

Correspondence: Dr Leloup, Department of Dermatology, 1 Place Alexis Ricordeau, Nantes University Hospital, 44000 Nantes, France (pauline.leloup@hotmail.fr).

Conflict of Interest Disclosures: None reported.

Additional Contributions: We are indebted to E. Cassagnau, MD, pathologist at Nantes University Hospital, France.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Disseminated violaceous plaques and papules on the thighs (A) and back (B).

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Dermal infiltrate of histiocytes around foci of collagen degeneration.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 3. Complete skin remission after 6 months of ustekinumab treatment.




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles